These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 19777735)

  • 41. Melatonergic drugs in clinical practice.
    Hardeland R; Poeggeler B; Srinivasan V; Trakht I; Pandi-Perumal SR; Cardinali DP
    Arzneimittelforschung; 2008; 58(1):1-10. PubMed ID: 18368944
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness.
    Kennedy SH; Rizvi SJ
    CNS Drugs; 2010 Jun; 24(6):479-99. PubMed ID: 20192279
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of melatonin in mood disorders and the antidepressant effects of agomelatine.
    Srinivasan V; De Berardis D; Shillcutt SD; Brzezinski A
    Expert Opin Investig Drugs; 2012 Oct; 21(10):1503-22. PubMed ID: 22876742
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients.
    Quera-Salva MA; Lemoine P; Guilleminault C
    Hum Psychopharmacol; 2010 Apr; 25(3):222-9. PubMed ID: 20373473
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical efficacy of agomelatine in depression: the evidence.
    den Boer JA; Bosker FJ; Meesters Y
    Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S21-4. PubMed ID: 16436936
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder.
    Kennedy SH; Emsley R
    Eur Neuropsychopharmacol; 2006 Feb; 16(2):93-100. PubMed ID: 16249073
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.
    Demyttenaere K; Corruble E; Hale A; Quera-Salva MA; Picarel-Blanchot F; Kasper S
    CNS Spectr; 2013 Jun; 18(3):163-70. PubMed ID: 23472671
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Agomelatine in the treatment of seasonal affective disorder.
    Pjrek E; Winkler D; Konstantinidis A; Willeit M; Praschak-Rieder N; Kasper S
    Psychopharmacology (Berl); 2007 Mar; 190(4):575-9. PubMed ID: 17171557
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.
    Udristoiu T; Dehelean P; Nuss P; Raba V; Picarel-Blanchot F; de Bodinat C
    J Affect Disord; 2016 Jul; 199():6-12. PubMed ID: 27054610
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synergistic mechanisms involved in the antidepressant effects of agomelatine.
    Tardito D; Molteni R; Popoli M; Racagni G
    Eur Neuropsychopharmacol; 2012; 22 Suppl 3():S482-6. PubMed ID: 22867907
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.
    Stahl SM; Fava M; Trivedi MH; Caputo A; Shah A; Post A
    J Clin Psychiatry; 2010 May; 71(5):616-26. PubMed ID: 20361916
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treating ADHD with agomelatine.
    Niederhofer H
    J Atten Disord; 2012 May; 16(4):346-8. PubMed ID: 22491963
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Agomelatine: An Astounding Sui-generis Antidepressant?
    Naveed M; Li LD; Sheng G; Du ZW; Zhou YP; Nan S; Zhu MY; Zhang J; Zhou QG
    Curr Mol Pharmacol; 2022; 15(7):943-961. PubMed ID: 34886787
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evidence of agomelatine's antidepressant efficacy: the key points.
    Eser D; Baghai TC; Möller HJ
    Int Clin Psychopharmacol; 2007 Oct; 22 Suppl 2():S15-9. PubMed ID: 17917562
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression.
    Stein DJ; Picarel-Blanchot F; Kennedy SH
    Hum Psychopharmacol; 2013 Mar; 28(2):151-9. PubMed ID: 23532747
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics?
    Srinivasan V; Brzezinski A; Pandi-Perumal SR; Spence DW; Cardinali DP; Brown GM
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):913-23. PubMed ID: 21453740
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinical experience of the use of agomelatine in the treatment of patients with depression and chronic brain ischemia].
    Antonen EG; Nikitina MV; Kruchek MM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(12):79-85. PubMed ID: 26978498
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept Study.
    Englisch S; Jung HS; Lewien A; Becker A; Nowak U; Braun H; Thiem J; Eisenacher S; Meyer-Lindenberg A; Zink M
    J Clin Psychopharmacol; 2016 Dec; 36(6):597-607. PubMed ID: 27805978
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic potential of agomelatine in epilepsy and epileptic complications.
    Vimala PV; Bhutada PS; Patel FR
    Med Hypotheses; 2014 Jan; 82(1):105-10. PubMed ID: 24314750
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder.
    Kennedy SH; Avedisova A; Giménez-Montesinos N; Belaïdi C; de Bodinat C;
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):553-63. PubMed ID: 24530273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.